Fuwo Pharmaceutical raises fresh round to fund oral breast-cancer drug trials
What's the deal? Shenzhen Fuwo Pharmaceutical has closed a new funding round backed by three investors: funds under Wuhan Hi-Tech State-owned HoldingDealroom has a profile for this one. Try Dealroom → Group, funds under Wuhan Innovation Investment Group, and TG Sino-Dragon FundDealroom has a profile for this one. Try Dealroom → II L.P., a US dollar fund managed by TG. The round was announced in October 2026.
What's the endgame? Fuwo is developing FWD1802, an oral SERD drug. The new capital will support its Phase III registrational trial, Phase Ib/II studies combining the drug with other therapies, and other innovative pipeline programmes.
Why now? Oral SERDs are an emerging class of hormone therapy for breast cancer, and Phase III registrational trials are capital-intensive. The round brings together state-backed Wuhan investors alongside TG's dollar fund, pairing local financial support with sector-focused expertise.
The signal: The deal shows continued investor appetite for late-stage Chinese oncology assets, with government-linked funds and clinical-focused backers co-investing to carry a novel drug candidate through to registration.
Read more: sohu.com
Image credit: foteih
